# Ionis Pharmaceuticals

反义治疗先驱；FDA 已受理其亚历山大病新药 zilganersen 的优先审评申请，Ionis 已将该药在美国以外所有国家的权益授权给 Recordati，延续 Spinraza（nusinersen，SMA）传承。

Source: https://cn.bioecon.ru/companies/ionis/
Updated: 2026-07-11

- 国家: United States
- 代码: IONS

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 产能 | 新的奥申赛德工厂规模是现有卡尔斯巴德工厂的两倍多 | https://ir.ionis.com/news-releases/news-release-details/ionis-announces-plan-new-manufacturing-facility-oceanside-calif |
| 认证 | Carlsbad主总部获LEED银级认证;新研发设施按LEED金级认证标准设计 | https://ionis.com/sites/default/files/2024-08/Ionis-2023-Corporate-Responsibility-Report.pdf |
| 监管批准 | Zilganersen已获FDA突破性疗法、孤儿药、罕见儿科疾病及快速通道资格认定;NDA已被受理并纳入优先审评,PDUFA日期为2026年9月22日 | https://ir.ionis.com/news-releases/news-release-details/ionis-announces-zilganersen-new-drug-application-alexander, https://ir.ionis.com/news-releases/news-release-details/zilganersen-granted-us-fda-fast-track-designation-people-living, https://www.neurologylive.com/view/fda-accepts-zilganersen-new-drug-application-priority-review-alexander-disease |
| 生产基地 | 美国加利福尼亚州卡尔斯巴德（现有研发化学与生产设施）；加利福尼亚州奥申赛德（新建生产设施） | https://ionis.com/about-us/corporate-responsibility/2025-Corporate-Responsiblity-Report.pdf, https://ir.ionis.com/news-releases/news-release-details/ionis-announces-plan-new-manufacturing-facility-oceanside-calif |
| 员工人数 | 约1,138至1,500名员工 [中等置信度] | https://ionis.com/media-center/corporate-factsheet.pdf |
| 营收 | 2025年全年为$9.44亿；2026年第一季度为$2.679亿 | https://ir.ionis.com/node/34176/pdf, https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm |

独立来源: neurologylive.com, sec.gov

## 技术

- [核酸药物（寡核苷酸）](https://cn.bioecon.ru/technology/nucleic-acid-therapeutics/)